Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial (TONE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hamburg, Germany, 20246
- University Medical Center Hamburg-Eppendorf
-
-
Baden-Wuerttemberg
-
Freiburg, Baden-Wuerttemberg, Germany, 79106
- Medical Center - University of Freiburg, Eye Hospital
-
Heidelberg, Baden-Wuerttemberg, Germany, 69120
- Heidelberg University Hospital, Department of Neurooncology
-
Tuebingen, Baden-Wuerttemberg, Germany, 72076
- Tuebingen University Hospital
-
-
Bayern
-
Erlangen, Bayern, Germany, 91054
- University Hospital Erlangen
-
Munich, Bayern, Germany, 81377
- University Hospital of Munich
-
Munich, Bayern, Germany, 81675
- University Hospital Klinikum rechts der Isar, Munich
-
-
Niedersachsen
-
Göttingen, Niedersachsen, Germany, 37075
- University Medical Center Göttingen
-
Hannover, Niedersachsen, Germany, 30625
- Hannover Medical School
-
-
Nordrhein-Westfalen
-
Duesseldorf, Nordrhein-Westfalen, Germany, 40225
- Duesseldorf University Hospital
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Germany, 55131
- University Medical Center of the Johannes Gutenberg University Mainz
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Patients eligible for inclusion in this trial must meet all of the following criteria:
- Written informed consent obtained according to international guidelines and local laws
- Male and female patients aged ≥ 18 to ≤ 50 years
- Patients with ON
- First symptoms of ON ≤ 10 days prior to the first administration of investigational product
- High contrast visual acuity (HCVA) of ≤ 0.5 (decimal system)
- Adequate OCT measurements available
Patients eligible for this trial must not meet any of the following criteria:
- Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial
- Simultaneous participation in another interventional trial which could interfere with this trial and/or participation in a clinical trial within the last 3 months before enrolment in this trial
- Refractive anomalies: Hyperopia > 5 dpt, myopia < -7 dpt, astigmatism > 3 dpt
- Media opacity
- Severe papillitis
- Previous ON
- Any other optic nerve and retinal disease
- Pre-existing MS or any other neurological disease
Congenital diseases:
- thrombophilia
- phenylketonuria
Acquired diseases:
- autoimmune diseases,
- cardiovascular diseases,
- diabetes mellitus,
- uncontrolled hypertension (with blood pressure > 140 / 90 mm Hg (cf. chapter 7.7.5)),
- any malignancy,
- epilepsy,
- known tuberculosis with ongoing or unknown activity,
- acute gastrointestinal ulceration within the last 3 months prior to randomisation,
- acute viral, bacterial or fungal infection,
- known infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus,
- history of colitis ulcerosa, diverticulitis, or acute enteroanastomosis,
- known osteoporosis,
- history of thromboembolic events,
- elevated haemoglobin level (>17 g/dl in men or >15 g/dl in women)
- polycythaemia
- any other significant illness potentially interfering with any trial assessment or trial treatment
- Performing semi-professional or professional sporting activities or physical training
- Pre-treatment with corticosteroids in the last 30 days prior to the onset of optic neuritis
- Pre-treatment with EPO
- Known or persistent abuse of medication, drugs or alcohol
- Active immunization within 2 weeks prior to randomisation
- Significant surgery within 4 weeks prior to randomisation
- Blood donation or bloodletting within 4 weeks prior to screening
- Pre-treatment with immunosuppressive or immunomodulatory agents
Persons who are in a relationship of dependence/employment with the sponsor or the investigator
This section concerns only female patients who are able to have a child:
- Current or planned pregnancy; nursing period within 3 months from investigational product administration
- Unwillingness to use one of the following safe combination methods of contraception within 3 months from investigational product administration to achieve a PEARL index of <1: female condom, diaphragm or coil, each used in combination with a spermicide; hormonal intra-uterine device or hormonal contraception in combination with a mechanical method of contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Erythropoietin alfa
Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v.
bolus injection on days 1, 2 and 3.
The dosage per day will be 33.000
IU in accordance with previous trials.
|
|
|
Placebo Comparator: Placebo
As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v.
administration) will be used.
It will be given as a bolus injection in the same manner as EPO.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global retinal nerve fibre layer thickness (RNFLT-G)
Time Frame: 6 months
|
Determination of the efficacy of erythropoietin compared to placebo given as add-on to methylprednisolone (standard of care) as assessed by measurement of global retinal nerve fibre layer thickness (RNFLT-G) in the affected eye 6 months after randomisation.
|
6 months
|
|
Low contrast visual acuity (LCVA)
Time Frame: 6 months
|
Determination of the efficacy of erythropoietin compared to placebo given as add-on to methylprednisolone (standard of care) as assessed by measurement of low contrast visual acuity (LCVA) in the affected eye 6 months after randomisation.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute values of the global retinal nerve fibre layer thickness
Time Frame: 6 months
|
6 months
|
|
|
Retinal nerve fibre layer thickness in the papillomacular bundle
Time Frame: 6 months
|
6 months
|
|
|
Retinal nerve fibre layer thickness in the temporal quadrant
Time Frame: 6 months
|
6 months
|
|
|
Total macular volume
Time Frame: 6 months
|
6 months
|
|
|
Visual acuity
Time Frame: 6 months
|
6 months
|
|
|
Contrast sensitivity
Time Frame: 6 months
|
6 months
|
|
|
Mean visual field defect
Time Frame: 6 months
|
6 months
|
|
|
Latency [ms] and amplitude [µV] of visual evoked potentials (VEP)
Time Frame: 6 months
|
6 months
|
|
|
Expanded Disability Status Scale (EDSS) score
Time Frame: 6 months
|
6 months
|
|
|
Quality of life
Time Frame: 6 months
|
Determined by NEI-VFQ-25
|
6 months
|
|
Safety
Time Frame: Screening until end of study
|
Assessment of AEs / SAEs
|
Screening until end of study
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Wolf A. Lagrèze, Prof., Eye Hospital, Medical Center - University of Freiburg
Publications and helpful links
General Publications
- Suhs KW, Hein K, Sattler MB, Gorlitz A, Ciupka C, Scholz K, Kasmann-Kellner B, Papanagiotou P, Schaffler N, Restemeyer C, Bittersohl D, Hassenstein A, Seitz B, Reith W, Fassbender K, Hilgers R, Heesen C, Bahr M, Diem R. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012 Aug;72(2):199-210. doi: 10.1002/ana.23573.
- Diem R, Molnar F, Beisse F, Gross N, Druschler K, Heinrich SP, Joachimsen L, Rauer S, Pielen A, Suhs KW, Linker RA, Huchzermeyer C, Albrecht P, Hassenstein A, Aktas O, Guthoff T, Tonagel F, Kernstock C, Hartmann K, Kumpfel T, Hein K, van Oterendorp C, Grotejohann B, Ihorst G, Maurer J, Muller M, Volkmann M, Wildemann B, Platten M, Wick W, Heesen C, Schiefer U, Wolf S, Lagreze WA. Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol. BMJ Open. 2016 Mar 1;6(3):e010956. doi: 10.1136/bmjopen-2015-010956.
- Lagreze WA, Kuchlin S, Ihorst G, Grotejohann B, Beisse F, Volkmann M, Heinrich SP, Albrecht P, Ungewiss J, Worner M, Hug MJ, Wolf S, Diem R; TONE study group. Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. Lancet Neurol. 2021 Dec;20(12):991-1000. doi: 10.1016/S1474-4422(21)00322-7.
- Wilhelm H, Schabet M. The Diagnosis and Treatment of Optic Neuritis. Dtsch Arztebl Int. 2015 Sep 11;112(37):616-25; quiz 626. doi: 10.3238/arztebl.2015.0616.
- Lagreze W, Diem R. [New aspects in the therapy of multiple sclerosis and optic neuritis]. Ophthalmologe. 2014 Aug;111(8):709-14. doi: 10.1007/s00347-013-2987-7. German.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P000053
- 2013-002515-10 (EudraCT Number)
- DRKS00005298 (Registry Identifier: German Clinical Trials Register (DRKS))
- 01KG1306 (Other Grant/Funding Number: Federal Ministry of Education and Research)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.